Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,311 signal articles · 52 in last 24h · 115,627 total before filter · latest 23m ago
52last 24h
1761last 7d
301● bullish (7d)
168● bearish (7d)
205publishers
AllMacro314Earnings817M&A102Regulatory25Product17Analyst25
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?
Simply Wall St.12d agobearish
SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

BWX Technologies (BWXT) Sells Medical Business And Signs New Thorium Fuel Deal
Simply Wall St.12d agobearish
BWX Technologies (BWXT) Sells Medical Business And Signs New Thorium Fuel Deal

BWX Technologies (NYSE:BWXT) has agreed to sell its medical business to Nordic Capital, while keeping a minority interest and technical involvement. The company has also signed a fuel fabrication agreement with Clean Core Thorium Energy related to future nuclear fuel deployments. These moves indicate a shift in BWX Technologies’ business mix toward core nuclear operations and advanced fuel capabilities. BWX Technologies enters these transactions with a share price of $173.79 and a 5 year...

SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium
Simply Wall St.12d agobearish
SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

NRG Energy (NRG) Misses Q2 Earnings Estimates
Zacks12d agobearish
NRG Energy (NRG) Misses Q2 Earnings Estimates

NRG (NRG) delivered earnings and revenue surprises of -10.24% and +27.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?